Johnson and Johnson ( JNJ ) discontinues its development of PurTox , a neurotoxin intended to compete with Allergan 's ( AGN ) $2B anti-wrinkle blockbuster. The company acquired the rights to the drug in 2009 with its buy of Mentor Corp
April 11 (Reuters) - Johnson & Johnson said on Friday it was ending its efforts to bring to market a rival drug to Allergan Inc 's popular Botox anti-wrinkle treatment.
include, Eli Lilly ( LLY ), Merck ( MRK ), P&G, Novartis ( NVS ), AstraZeneca ( AZN ), Sanofi-Aventis ( SNY ), Allergan ( AGN ) and Bausch & Lomb. Here's a quick rundown. Sustained Release Success Across Many Disease Indications Novartis
products through the development and clinical trial phases. His background includes stints at MAP Pharmaceuticals (acquired by Allergan ), Inspire Pharmaceuticals (acquired by Merck), Sepracor (acquired by Dainippon Sumitomo Pharma) as well as several members
WASHINGTON, March 31 (Reuters) - The U.S. Supreme Court on Monday left intact an appeals court ruling that endorsed patent protections for Combigan, Allergan Inc 's glaucoma drug.
areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease. ( AGN ) ( AMGN ) ( BAX ) ( BIIB ) ( CELG ) ( LLY ) ( GSK ) ( JNJ ) ( NVS ) ( NVO ) ( PFE ) ( OTCQX:RHHBY ) ( SNY ) ( MRK ) ( SHPG
bondholders of merger targets. Specifically, we highlight Abbott Laboratories ABT (rating: AA-, narrow moat), Allergan AGN (rating: AA-, wide moat), Teva Pharmaceutical TEVA (rating: A-, narrow moat), and Zoetis ZTS (rating
Q&A with Sam Isaly , the manager of Eaton Vance health sciences ETHSX . He still likes biotechs and pharma. His picks are AGN , ESRX, ISRG, REGN, RHHBY ; also mentioned are BIIB, GILD, PCYC, MDVN, ALPMY, ABBV, JAZZ, PRGO, ACT, JNJ, BMY
By Cockrell Group : We are remaining positive on the outlook of Supernus Pharmaceuticals' (NASDAQ: SUPN ) shares after the Company released its 4Q13 and FY2013 results. Reported revenues for 2013 were approximately $12 million, which exceeded analyst estimates of $8.3 million. Shares of the company
partnerships for both development and marketing: Pfizer/Takeda for Fusilev, Bayer for Zevalin, Topotarget for Belinostat and Allergan for Apaziquone. Moreover, OncoRx is a subsidiary of SPPI located in India that functions as a dependable resource for SPPI